Study of vericiguat safety in Japanese chronic heart failure patients
Treatments studied
Part of Heart & circulation clinical trials.
This study checks how safe the medicine vericiguat is for Japanese people with chronic heart failure when used in everyday care. It compares patients who receive vericiguat with patients who continue standard treatments without vericiguat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a patient in Japan (Japanese people only).
- You have chronic heart failure and are already on standard heart failure treatment.
- Your heart failure is at NYHA class II, III, or IV (not class I).
- Your heart ultrasound shows left ventricular ejection fraction (LVEF) under 45%.
- You have not taken vericiguat before (either arm).
- You are not in another interventional (investigational) drug study and you will give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called vericiguat (a pill) to see if it can improve the heart's shape and function in people with heart failure and a weakened pump. You would keep taking your usual heart medications plus the study drug.
This study looks at how well Verquvo (vericiguat) works in daily life for Korean adults with chronic heart failure and a weak heart pump. It’s for people whose heart failure has recently gotten worse and who are starting Verquvo for the first time.
This study tests whether adding a new medicine called vericiguat to standard heart failure treatments helps patients with heart failure feel better and avoid hospital stays. Vericiguat is a pill that may improve heart function and reduce symptoms like shortness of breath and fatigue.
This study tests whether the drug vericiguat helps people with heart failure after a heart attack. The trial looks at people whose heart pumping is weak and who have symptoms despite standard treatment.
This trial tests how a medication called vericiguat works in people with both chronic kidney disease and heart failure. It aims to see if the drug helps manage these conditions together.
This trial tests whether vericiguat helps children with chronic heart failure caused by weaker left heart pumping. It also checks safety and how the medicine behaves in the body (dose and processing).
Hear when a new Chronic Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.